Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer

TRC105 is an endoglin-targeting drug that possesses anti-angiogenic and antitumor potential. Analysis of the initial phase I trial of TRC105 demonstrated good tolerability and efficacy in cancer patients. In this report, we analyzed multiple circulating biomarkers at baseline, cycle 2 day 1 (C2D1),...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Liu, Yingmiao, Starr, Mark D, Brady, John C, Dellinger, Andrew, Pang, Herbert, Adams, Bonne, Theuer, Charles P, Lee, Nam Y, Hurwitz, Herbert I, Nixon, Andrew B
Формат: Artigo
Язык:Inglês
Опубликовано: BlackWell Publishing Ltd 2014
Предметы:
Original Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4101749/
https://ncbi.nlm.nih.gov/pubmed/24574330
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.207
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы